Pfizer has entered into collaboration with MicuRx and Cumencor Pharmaceuticals to discover novel therapeutic agents to treat multi-drug-resistant tuberculosis (MDR-TB).
Under the agreement, Pfizer will provide upfront funding for the discovery and preclinical development of novel antibiotics to treat MDR-TB, and payments based on the development and commercialisation of any antibiotics developed through the collaboration.
The World Health Organization estimates that China accounts for more than 25% of all worldwide cases of MDR-TB, mainly because of insufficient supervision and lack of adherence to therapeutic TB regimens.
Cumencor Pharmaceuticals is a China-based biotechnology company applying MicuRx’s proprietary technology platform to discover and develop novel antibiotics for MDR-TB.
All collaboration research will be conducted at the ZhangJiang High-Tech Park in Shanghai, China.